About: Development of vaccines for SARS-CoV-2

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Development of vaccines for SARS-CoV-2 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Development of vaccines for SARS-CoV-2
Creator	Mahalingam, Suresh Makino, Shinji Liu, Xiang Hann Ng, Wern Koh, Gavin
Source	Medline; PMC
abstract	COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a few months, huge efforts and resources by government, academia, and industry have been thrown into the race to develop a vaccine. This brief review summarizes and discusses the array of technologies being applied to vaccine development, highlighting the strengths and weaknesses of the various approaches.
has issue date	2020-08-17(xsd:dateTime)
bibo:doi	10.12688/f1000research.25998.1
bibo:pmid	32850116
has license	cc-by
sha1sum (hex)	78800c50b97cd5bd2ae016995c26a2569411ecce
schema:url	https://doi.org/10.12688/f1000research.25998.1
resource representing a document's title	Development of vaccines for SARS-CoV-2
has PubMed Central identifier	PMC7431966
has PubMed identifier	32850116
schema:publication	F1000Res
resource representing a document's body	covid:78800c50b97cd5bd2ae016995c26a2569411ecce#body_text
is schema:about of	named entity 'Development' named entity 'globally' named entity 'development' named entity 'HUGE' named entity 'RACE' named entity 'BRIEF' named entity 'GLOBALLY' named entity 'STRENGTHS' named entity 'COUNTRIES' named entity 'REV' named entity 'ACADEMIA' named entity 'RAPIDLY' named entity 'SPREAD' named entity 'VARIOUS' named entity 'MONTHS' named entity 'SARS-COV-2' named entity 'PANDEMIC' named entity 'RECENTLY' named entity 'PEER REVIEW' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'natural immunity' named entity 'vaccines' named entity 'SARS-CoV-2' named entity 'peer review' named entity 'vaccines' named entity 'United Kingdom' named entity 'point mutations' named entity 'SARS-CoV-2' named entity 'viral vectors' named entity 'adverse events' named entity 'COVID-19' named entity 'DNA-based vaccination' named entity 'University of Oxford' named entity 'clinical testing' named entity 'Coalition for Epidemic Preparedness Innovations' named entity 'novel-coronavirus' named entity 'protein' named entity 'live attenuated' named entity 'SARS-CoV-2' named entity 'immunocompromised patients' named entity 'SARS-CoV-2' named entity 'immune responses' named entity 'RNA-based' named entity 'coding sequence' named entity 'COVID' named entity 'vaccine' named entity 'coronaviruses' named entity 'strong safety' named entity 'coronavirus disease' named entity 'COVID-19 vaccine' named entity 'SARS-CoV-2' named entity 'COVID-19 vaccine' named entity 'phase I trials' named entity 'clinical trials' named entity 'pre-clinical studies' named entity 'malaria' named entity 'vaccine' named entity 'Sinovac' named entity 'vaccine' named entity 'protein subunit' named entity 'serum' named entity '2 billion' named entity 'hepatitis B vaccine' named entity 'infection' named entity 'H1N1' named entity 'control group' named entity 'gRNA' named entity 'Europe' named entity 'strong safety' named entity 'SARS-CoV-2' named entity 'proto-oncogenes' named entity 'vaccine' named entity 'vaccination' named entity 'pre-clinical studies' named entity 'vaccine' named entity 'immune response'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software